Published in Blood on April 29, 2011
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Implementing personalized medicine in a cancer center. Cancer J (2011) 1.69
Epidemiology of myelodysplastic syndromes. Am J Med (2012) 1.29
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol (2014) 1.02
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst (2013) 0.98
Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res (2011) 0.93
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol (2012) 0.91
Incidence of myelodysplastic syndrome in Japan. J Epidemiol (2014) 0.88
Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep (2015) 0.86
Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. Cancer Epidemiol (2016) 0.84
Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. BMC Genomics (2015) 0.84
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia (2016) 0.83
The incidence of myelodysplastic syndromes in Western Greece is increasing. Ann Hematol (2013) 0.82
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Oncologist (2015) 0.82
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res (2012) 0.82
New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res (2013) 0.81
Alcohol consumption and risk of myelodysplastic syndromes: A meta-analysis of epidemiological studies. Mol Clin Oncol (2014) 0.81
Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes. Leuk Lymphoma (2013) 0.79
Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). Curr Hematol Malig Rep (2014) 0.79
Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun (2017) 0.78
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. Haematologica (2012) 0.78
Biology of BM failure syndromes: role of microenvironment and niches. Hematology Am Soc Hematol Educ Program (2014) 0.78
Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). Leuk Res (2014) 0.77
Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy. Leuk Lymphoma (2013) 0.77
Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep (2016) 0.76
Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits (2012) 0.76
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. Oncologist (2017) 0.75
Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. Breast Cancer Res Treat (2015) 0.75
The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate. Blood Cancer J (2013) 0.75
A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. Am J Blood Res (2015) 0.75
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer (2016) 0.75
Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D. J Oncol Pract (2015) 0.75
Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line. Mol Med Rep (2016) 0.75
BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-κB pathway proteins. Exp Ther Med (2014) 0.75
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia (2015) 0.75
Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry. Medicine (Baltimore) (2017) 0.75
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. J Clin Oncol (2017) 0.75
[Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification]. Pathologe (2013) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst (2007) 4.97
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood (2008) 4.41
Myelodysplastic syndromes: incidence and survival in the United States. Cancer (2007) 3.89
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol (2010) 2.93
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst (2008) 2.64
Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer (2010) 2.17
Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania. Leuk Res (2009) 1.53
Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol (2001) 1.30
Myelodysplasic syndromes: a comprehensive review. Blood Rev (2005) 1.11
Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol (2010) 1.01
Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer (2010) 0.96
Ascertainment of patients with myelodysplastic syndromes. J Clin Oncol (2010) 0.95
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet (2011) 4.70
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood (2008) 4.41
Is complementary and alternative medicine (CAM) cost-effective? A systematic review. BMC Complement Altern Med (2005) 3.01
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood (2012) 2.51
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood (2007) 2.37
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res (2013) 2.24
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood (2004) 2.23
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol (2009) 2.03
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood (2012) 1.98
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood (2011) 1.74
Implementing personalized medicine in a cancer center. Cancer J (2011) 1.69
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res (2010) 1.63
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol (2012) 1.61
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood (2011) 1.59
STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood (2013) 1.59
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood (2007) 1.54
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer (2011) 1.51
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol (2006) 1.42
The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer (2010) 1.39
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2008) 1.39
Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol (2011) 1.35
Practitioner empathy and the duration of the common cold. Fam Med (2009) 1.33
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol (2011) 1.29
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol (2010) 1.26
Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev (2012) 1.25
A quantitative description of the percentage of breast density measurement using full-field digital mammography. Acad Radiol (2011) 1.25
Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health (2011) 1.20
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica (2013) 1.18
Comparative analysis of breast cancer risk factors among Hispanic and non-Hispanic white women. Cancer (2010) 1.16
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer (2010) 1.14
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol (2010) 1.14
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica (2012) 1.13
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol (2009) 1.13
Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep (2005) 1.12
Calibrated measures for breast density estimation. Acad Radiol (2011) 1.10
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer (2011) 1.10
Lenalidomide--the phoenix rises. N Engl J Med (2007) 1.09
Argentine valuation of the EQ-5D health states. Value Health (2008) 1.08
Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program (2003) 1.07
Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis (2011) 1.05
Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev (2012) 1.04
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett (2009) 1.04
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res (2005) 1.00
Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol (2011) 1.00
Infertility evaluation and treatment among women in the United States. Fertil Steril (2013) 0.98
Risk factors for incident condyloma in a multinational cohort of men: the HIM study. J Infect Dis (2012) 0.98
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol (2011) 0.97
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res (2008) 0.97
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk (2013) 0.96
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood (2013) 0.96
Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol (2009) 0.96
Role of lenalidomide in the treatment of myelodysplastic syndromes. Semin Oncol (2011) 0.96
Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol (2013) 0.96
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer (2011) 0.95
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res (2011) 0.95
Racial and ethnic disparities in the incidence of invasive cervical cancer in Florida. Cancer (2009) 0.94
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol (2013) 0.94
Telomere length in myelodysplastic syndromes. Leuk Lymphoma (2011) 0.93
Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer (2005) 0.93
Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res (2011) 0.93
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol (2013) 0.92
Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist (2011) 0.92
Case-control study of genus-beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. Int J Cancer (2013) 0.91
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood (2012) 0.91
Concordance of human papillomavirus types detected on the surface and in the tissue of genital lesions in men. J Med Virol (2013) 0.90
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol (2014) 0.89
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol (2012) 0.89
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res (2013) 0.89
Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study. J Clin Virol (2013) 0.88
Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin. J Invest Dermatol (2013) 0.87
Management of RBC-transfusion dependence. Hematology Am Soc Hematol Educ Program (2007) 0.87
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control (2006) 0.87
Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res (2008) 0.87
Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes (2009) 0.87
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol (2012) 0.87
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A (2013) 0.87
Risk factors for cutaneous human papillomavirus seroreactivity among patients undergoing skin cancer screening in Florida. J Infect Dis (2010) 0.86
Biology and treatment of the 5q- syndrome. Expert Rev Hematol (2011) 0.86
Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr (2004) 0.86
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? Curr Hematol Malig Rep (2010) 0.84
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol (2012) 0.84
Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin. J Infect Dis (2012) 0.84
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res (2007) 0.83
Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study. BMC Cancer (2012) 0.83
Erythropoietin receptor signaling is membrane raft dependent. PLoS One (2012) 0.83
Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk (2013) 0.83
Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep (2011) 0.83
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res (2013) 0.83
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol (2012) 0.82
Immune dysregulation in myelodysplastic syndrome. Hematol Rep (2010) 0.82
Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc (2005) 0.81
Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives. Clin Cancer Res (2002) 0.81